AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 44.51 USD 0.36% Market Closed
Market Cap: 1.2B USD

AnaptysBio Inc
Other Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AnaptysBio Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Other Current Assets
$6m
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
19%
Abbvie Inc
NYSE:ABBV
Other Current Assets
$5.2B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Current Assets
$3.6B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Assets
$709.4m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Assets
$1.4B
CAGR 3-Years
47%
CAGR 5-Years
44%
CAGR 10-Years
25%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
HIDDEN
Show

See Also

What is AnaptysBio Inc's Other Current Assets?
Other Current Assets
6m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Other Current Assets amounts to 6m USD.

What is AnaptysBio Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
19%

Over the last year, the Other Current Assets growth was -6%. The average annual Other Current Assets growth rates for AnaptysBio Inc have been -2% over the past three years , -4% over the past five years , and 19% over the past ten years .

Back to Top